Literature DB >> 16366759

Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence.

Lisa A Marsch1, Mary Ann Chutuape Stephens, Timothy Mudric, Eric C Strain, George E Bigelow, Rolley E Johnson.   

Abstract

This study examined (1) predictors of treatment outcome for opioid-dependent participants in a single-site controlled trial comparing methadone, buprenorphine, and LAAM treatments and (2) the extent to which various subpopulations of patients may have more successful outcomes with each medication. The relationships between patient demographics, drug use history, and psychological status and outcome measures of treatment retention, opiate use, and cocaine use were assessed. We believe this study to be the first to demonstrate that predictors of treatment success appear to be largely similar in LAAM, buprenorphine, and methadone treatment for opioid dependence. We did not find any factors that would strongly guide selection of one medication over others. Copyright 2005 APA, all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16366759     DOI: 10.1037/1064-1297.13.4.293

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  23 in total

1.  Superior methadone treatment outcome in Hmong compared with non-Hmong patients.

Authors:  Gavin Bart; Qi Wang; James S Hodges; Chris Nolan; Gregory Carlson
Journal:  J Subst Abuse Treat       Date:  2012-01-28

2.  Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence.

Authors:  Ryan Schwarz; Alexei Zelenev; R Douglas Bruce; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2012-04-24

3.  Emerging adult age status predicts poor buprenorphine treatment retention.

Authors:  Zev Schuman-Olivier; Roger D Weiss; Bettina B Hoeppner; Jacob Borodovsky; Mark J Albanese
Journal:  J Subst Abuse Treat       Date:  2014-05-20

Review 4.  Maintenance medication for opiate addiction: the foundation of recovery.

Authors:  Gavin Bart
Journal:  J Addict Dis       Date:  2012

5.  Is residential treatment effective for opioid use disorders? A longitudinal comparison of treatment outcomes among opioid dependent, opioid misusing, and non-opioid using emerging adults with substance use disorder.

Authors:  Zev Schuman-Olivier; M Claire Greene; Brandon G Bergman; John F Kelly
Journal:  Drug Alcohol Depend       Date:  2014-09-18       Impact factor: 4.492

6.  Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.

Authors:  Brantley P Jarvis; August F Holtyn; Meredith S Berry; Shrinidhi Subramaniam; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman
Journal:  J Subst Abuse Treat       Date:  2017-04-20

7.  Predictors of outcome from computer-based treatment for substance use disorders: Results from a randomized clinical trial.

Authors:  Sunny Jung Kim; Lisa A Marsch; Honoria Guarino; Michelle C Acosta; Yesenia Aponte-Melendez
Journal:  Drug Alcohol Depend       Date:  2015-09-26       Impact factor: 4.492

Review 8.  Recommendations for Substance Abuse and Pain Control in Patients with Chronic Pain.

Authors:  Nalini Vadivelu; Alice M Kai; Gopal Kodumudi; Dan Haddad; Vijay Kodumudi; Niketh Kuruvilla; Alan David Kaye; Richard D Urman
Journal:  Curr Pain Headache Rep       Date:  2018-03-19

9.  Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.

Authors:  T V Parran; C A Adelman; B Merkin; M E Pagano; R Defranco; R A Ionescu; A G Mace
Journal:  Drug Alcohol Depend       Date:  2009-08-29       Impact factor: 4.492

10.  Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.

Authors:  Jessica A Dreifuss; Margaret L Griffin; Katherine Frost; Garrett M Fitzmaurice; Jennifer Sharpe Potter; David A Fiellin; Jeffrey Selzer; Mary Hatch-Maillette; Susan C Sonne; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2013-01-18       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.